Biologics
  • tumor necrosis factor alpha (TNF-alpha), which is a protein that promotes inflammation in the body
  • T cells, which are white blood cells
  • interleukins, which are cytokines (small inflammatory proteins) involved in psoriasis

Risankizumab-rzaa (Skyrizi)

approvedphototherapy
  • upper respiratory infections
  • reactions at the injection site
  • headache
  • tiredness
  • fungal infections

Certolizumab pegol (Cimzia)

approvedCimzia
  • upper respiratory tract infections
  • rash
  • urinary tract infections (UTIs)

Tildrakizumab-asmn (Ilumya)

FDA-approvedside effects of Ilumya
  • reactions at the injection site
  • upper respiratory infections
  • diarrhea

Guselkumab (Tremfya)

FDA-approved
  • headache
  • upper respiratory infections
  • reactions at the injection site
  • joint pain
  • diarrhea
  • stomach flu

Brodalumab (Siliq)

FDA-approved
  • have moderate to severe plaque psoriasis
  • are candidates for phototherapy or systemic therapy
  • their psoriasis doesn’t respond to other systemic therapies
clinical trials

Ixekizumab (Taltz)

FDA-approvedmultiple clinical studies
  • upper respiratory infections
  • reactions at the injection site
  • fungal infections

Biosimilars to adalimumab (Humira)

  • adalimumab-adaz (Hyrimoz)
  • adalimumab-adbm (Cyltezo)
  • adalimumab-afzb (Abrilada)
  • adalimumab-atto (Amjevita)
  • adalimumab-bwwd (Hadlima)

Biosimilars to etanercept (Enbrel)

Biosimilars to infliximab (Remicade)

  • infliximab-abda (Renflexis)
  • infliximab-axxq (Avsola)
  • infliximab-dyyb (Inflectra)
Remicadeapproved

Halobetasol propionate-tazarotene lotion, 0.01%/0.045% (Duobrii)

approved
  • pain at the application site
  • rash
  • folliculitis, or inflamed hair follicles
  • wearing away of the skin where the lotion is applied
  • excoriation, or skin picking

Halobetasol propionate foam, 0.05% (Lexette)

approvedbecame available

Halobetasol propionate lotion, 0.01% (Bryhali)

approved
  • dryness
  • flaking
  • inflammation
  • plaque buildup
  • burning
  • stinging
  • itching
  • dryness
  • upper respiratory tract infections
  • high blood sugar

Betamethasone dipropionate spray, 0.05% (Sernivo)

approvedbetamethasone
  • itching
  • burning
  • stinging
  • pain at the application site
  • skin atrophy

Calcipotriene foam, 0.005% (Sorilux)

approvalapproved

Calcipotriene-betamethasone dipropionate foam, 0.005%/0.064% (Enstilar)

approved
  • itching
  • folliculitis
  • rash with raised red bumps or hives
  • worsening psoriasis

Calcipotriene-betamethasone dipropionate topical suspension, 0.005%/0.064% (Taclonex)

FDA-approvedFDA-approved
  • itching
  • burning
  • irritation
  • redness
  • folliculitis

Ustekinumab (Stelara)

approvedustekinumabStelara2015 study
  • Adolescents who weigh less than 60 kilograms (132 pounds) get 0.75 milligrams (mg) per kilogram of weight.
  • Adolescents who weigh between 60 kg (132 lbs.) and 100 kg (220 lbs.) get a 45-mg dose.
  • Adolescents who weigh more than 100 kg (220 lbs.) get 90 mg, which is the standard dose for adults of the same weight.
  • colds and other upper respiratory tract infections
  • headache
  • tiredness

Etanercept (Enbrel)

approvedEnbrel2016 study

Bimekizumab

90 percent disease severity

Calcipotriene-betamethasone dipropionate cream, 0.005%/0.064% (Wynzora)

phase III study

JAK inhibitors

  • psoriatic arthritis
  • rheumatoid arthritis
  • ulcerative colitis
baricitinibOlumiantstudies